Abstract 2270P
Background
Pancreatic Adenocarcinoma (PAAD) is a highly fatal disease and often associated with a poor prognosis. The development of diabetes mellitus (DM) is an important risk factor. There have been studies exploring markers or prognostic models that affect the prognosis of patients with pancreatic cancer, but there are few studies on pancreatic cancer-associated diabetes mellitus (PCDM) patients.
Methods
The differentially expressed genes (DEGs) between DM and non-DM were detected and selected to build model. PCDM patients were randomly divided into training (70%) and test cohort (30%). Then the univariate COX was performed to screen OS associated genes (p < 0.05) in the training cohort. The LASSO-penalized COX regression and ten-fold cross validation were used to train and select models. The risk score was calculated and verified in both training and test cohort. GSVA, ESTIMATEScore, CIBERSORT and ssGSEA were used to compare the tumor microenvironment (TME). Moreover, the value of genes used in the model was detected on single cell level.
Results
Totally 197 patients (including 60 with DM) were enrolled, 23 genes from DEGs were related to the OS of PCDM patients in the training cohort, and 10 genes were selected to construct the risk model. The risk score for each subject was calculated as follow: risk score=0.434*ACACA+0.119*ATG7+0.373*DEFB123+0.135*FSTL3-0.168*NIPSNAP3B-0.069*RASSF1+0.225*RBPJ+0.364*SLC35F2-0.168*SLC37A1-0.145*ZC3H12D. The C-index was 0.83 in the training cohort (hazard ratio [HR] = 7.61, p < 0.001) and 0.76 in the test cohort (HR = 3.22, p = 0.015). According to the median value -0.054, PCDM patients were split into different risk groups, and patients in the low-risk group showed more enriched T cell related pathways (60 vs 1), higher ImmuneScore (p < 0.001), and more CD8 positive T cell infiltration (CIBERSORT: p < 0.001; ssGSEA: p < 0.001). We calculated the score of genes used in the model in single cells. Malignant cells with the highest score (top 10%) had enhanced activities of angiogenesis.
Conclusions
The prognostic model showed potential value in predicting the OS of patients with PCDM. Patients with low-risk score had a hotter TME and might benefit from immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2267P - Coronary heart disease and risk of lung cancer: A two-sample Mendelian randomization study
Presenter: Cai Chen Li
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08
2273P - Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
Presenter: Marta González Rodríguez
Session: Poster session 08